Virtual Symposium: Tackling Diabetic Kidney Disease Progression: Challenges, Advances, and Novel Approaches

Diabetic kidney disease (DKD) is one of the most common complications of diabetes, affecting up to 50% of persons with diabetes, and leading to increased morbidity and mortality. Despite optimized glycemic control and renin-angiotensin-aldosterone system (RAAS) inhibitor therapy, many patients with DKD progress to kidney failure. Recent advances in the understanding of disease pathophysiology have opened up new avenues of treatment, including mineralocorticoid receptor antagonism, which have the potential to improve outcomes for patients with DKD. In particular, non-steroidal mineralocorticoid receptor antagonists (MRAs) have shown promise in DKD, as demonstrated in recent clinical trial results, and several phase III trials are ongoing.

During this symposium, experts will discuss recent and emerging clinical trial data with MRAs in DKD, particularly non-steroidal MRAs. In addition, they will provide an overview about the underlying pathophysiology, how to identify patients at high-risk, and the current management of DKD.

This activity is part of the DKD Digital Highlights Hub.

Target Audience

This activity is designed for US-based healthcare professionals, including primary care clinicians (PCPs), nurse practitioners (NPs), physician assistants (PAs), endocrinologists, diabetologists, pharmacists, cardiologists, lipidologists, and other allied health professionals.

Learning Objectives

After completing this activity, the participant should be better able to:

  • Identify T2DM patients at risk for kidney disease or kidney disease progression
  • Develop appropriate treatment options for patients with DKD based on current guideline recommendations and available treatment options
  • Summarize the efficacy, safety, and mechanisms of action of emerging treatment options for DKD
Course summary
Available credit: 
  • 1.00 ACPE Pharmacy
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 ANCC
  • 1.00 CDE
  • 1.00 Participation
Course opens: 
01/20/2021
Course expires: 
01/20/2022
Rating: 
0

George L. Bakris, MD (Chair)
Professor of Medicine
Director, ASH Comprehensive Hypertension Center
University of Chicago Medicine
Chicago, IL

Dr. Bakris discloses the following: 

  • Consulting Fees: Merck, Novo Nordisk, DiaMedica, Bayer, Relypsa
  • Contracted Research: Bayer, Novo Nordisk, Vascular Dynamics-all to UC


Rajiv Agarwal, MD, MS
Professor of Medicine
Indiana University School of Medicine and VA Medical Center
Indianapolis, IN

Dr. Agarwal discloses the following: 

  • Consulting Fees: AKEBIA THERAPEUTICS INC; ASTRAZENECA AB; ASTRAZENECA PHARMACEUTICALS LP; BAYER HEALTHCARE PHARMACEUTICALS INC.; BOEHRINGER INGELHEIM B.V.; BOEHRINGER INGELHEIM INTERNATIONAL GMBH
  • BOEHRINGER INGELHEIM PHARMA GMBH & CO.KG; BOEHRINGER INGELHEIM PHARMACEUTICALS, INC.; ELI LILLY AND COMPANY; IRONWOOD PHARMACEUTICALS, INC; JANSSEN RESEARCH & DEVELOPMENT, LLC; RELYPSA, INC. SANOFI VIFOR
  • FRESENIUS MEDICAL CARE RENAL PHARMA LTD.; MERCK & Co; LEXICON; REATA
  • Fees for Non-CME/CE Services Received Directly from a Commercial Interest or their Agents (e.g. speakers’ bureaus): FRESENIUS USA MARKETING, INC

 

Janet B. McGill, MD
Professor of Medicine
Washington University School of Medicine
St. Louis, MO

Dr. McGill discloses the following: 

  • Consulting Fees: Bayer, Boehringer Ingelheim, Lilly
  • Fees for Non-CME/CE Services Received Directly from a Commercial Interest or their Agents (e.g. speakers’ bureaus): Metavant, Dexcom, Novo Nordisk, Janssen

 

 

 

ESTIMATED TIME TO COMPLETE ACTIVITY
1.0 hour

EDUCATIONAL GRANT SUPPORT
Supported by an educational grant from Bayer HealthCare Pharmaceuticals Inc.

JOINT ACCREDITATION STATEMENT
image   image   image



In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and Tarsus Cardio Inc. dba Cardiometabolic Health Congress (CMHC). Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

PHYSICIAN CONTINUING MEDICAL EDUCATION
The Postgraduate Institute for Medicine designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credits™. Physicians should claim only the credits commensurate with the extent of their participation in the activity.

CONTINUING NURSING EDUCATION
The maximum number of hours awarded for this Continuing Nursing Education activity is 1.0 contact hours. Pharmacotherapy contact hours for Advanced Practice Registered Nurses will be designated on your certificate. 

CONTINUING PHARMACY EDUCATION
Postgraduate Institute for Medicine designates this continuing education activity for 1.0 contact hour(s) (.10 CEUs) of the Accreditation Council for Pharmacy Education.

This is an knowledged-based activity. Universal Activity Numbers (UAN): #JA4008162-9999-20-2496-H01-P

For Pharmacists: Upon completing the post-test and the activity evaluation form, transcript information will be sent to the NABP CPE Monitor Service within 4 – 6 weeks.

CONTINUING DIETICIAN EDUCATION
This program offers 1.0 CPEUs for dieticians.

ABIM MOC CERTIFICATION
image
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.0 MOC points in the American Board of Internal Medicine's (ABIM) maintenance of certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

DISCLOSURE OF CONFLICTS OF INTEREST
Postgraduate Institute for Medicine (PIM) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to PIM policy. PIM is committed to providing its learners with high quality activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.

The PIM planners and managers have nothing to disclose. The CMHC planners and managers have nothing to disclose.

DISCLOSURE OF UNLABELED USE
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

DISCLAIMER
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management.  Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient's conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities.

METHOD OF PARTICIPATION & REQUEST FOR CREDIT
During the period January 20, 2021 through January 20, 2022, participants must read the learning objectives and faculty disclosures, study the educational activity, obtain a score of 75% or better on the post-test, and complete the evaluation. Upon completing, your certificate will be available for print. For questions about receiving certificates, please contact us at CMHC_Eval@cardiometabolichealth.org.

For questions about the accreditation of this activity, please visit www.pimed.com.

For Pharmacists: Please complete the evaluation instructions above. Upon registering and completing the activity evaluation, your transcript information will be sent to the NABP CPE Monitor Service within 4-6 weeks.

Available Credit

  • 1.00 ACPE Pharmacy
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 ANCC
  • 1.00 CDE
  • 1.00 Participation
Please login or register to take this course.

Required Hardware/software

This online activity must be viewed with the latest version of Chrome, Firefox or Internet Explorer. If you do not have these browsers, you can download Chrome here, Firefox here and Internet Explorer here. Optimal viewing requires a broadband connection of at least 3 Mbps and a 1 GHz processor with 1 GB RAM.